中文From July 30th to August 1st, 2024, the 76th American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo (ADLM, formerly known as AACC) concluded successfully in Chicago, USA. ADLM - Clinical Lab Expo is one of the largest and most influential annual events in the global clinical diagnostics field. It attracts over 20,000 international professionals from 110 countries each year, showcasing the latest advancements in clinical laboratory testing technology and in vitro diagnostic products.
During this event, Igenesis presented its self-developed Galaxy Automated Fully Enclosed qPCR System, along with a range of reagents, at booth 1664. This impressive display highlighted China’s innovation and technological prowess in point-of-care molecular diagnostics products, while also fostering further collaboration with the American and Latin American markets.
The booth was bustling with visitors, and Igenesis’s international team engaged attendees with lively and interesting presentations on their overall solutions and technological innovations in point-of-care molecular diagnostics (POCT). The unique design concepts, outstanding performance, and versatile applications garnered widespread acclaim and strong interest from the exhibition attendees.
Exhibition highlights
Galaxy Automated Fully Enclosed qPCR System
Galaxy Automated Fully Enclosed qPCR System, equipped with iCassette (PCR-fluorescent probe method). With only 3 steps to complete the entire process of nucleic acid extraction, purification, and fluorescence PCR amplification. It operates in a fully automated and enclosed manner, breaking free from the limitations of traditional laboratories and achieving a workflow from sample input to result out. By simplifying the process and reducing complexity, this system enhances diagnostic efficiency. A diverse range of reagents have received CE-IVD certification, and the test items include HPV screening, tuberculosis screening, respiratory pathogen detection, intestinal pathogen detection, and Carba-R drug resistance testing.
iCassette®
Open platform, the highlight lies in its compatibility and flexibility. By integrating third-party PCR detection reagents into iCassette, it creates an integrated molecular point-of-care testing (POCT) product. When combined with the Galaxy Automated Fully Enclosed qPCR System, it streamlines nucleic acid testing workflows, resulting in significant time and cost savings.
Diversified application scenarios. Ready-to-use multiplex pathogen detection test kits empower clinical institutions, disease control centers, customs ports, and immigration inspection and quarantine bureaus to conduct various infectious disease testing projects. Overall, this enhances their testing capabilities and emergency response readiness.
iCassette
Igenesis’s journey toward the international market has never stopped. Currently, Igenesis holds over 120 domestic and foreign intellectual property patents, more than 30 domestic and foreign medical device registrations and 21 EU CE certifications. In the future, Igenesis will adhere to its core values of integrity, excellence, innovation, and win-win collaboration. The company is dedicated to unlocking the boundless potential of genetic testing, offering secure, rapid, convenient, and precise comprehensive solutions for immediate molecular diagnostics.
The exhibition ended perfectly,
looking forward to meeting next year!
Post time: Aug-08-2024